Table of Contents
Pathology Research International
Volume 2011, Article ID 246936, 7 pages
http://dx.doi.org/10.4061/2011/246936
Clinical Study

Human Papillomavirus Types 52 and 58 Are Prevalent in Uterine Cervical Squamous Lesions from Japanese Women

1Department of Obstetrics and Gynecology, National Hospital Organization Kure Medical Center and Chugoku Cancer Center, Kure 737-0023, Japan
2Department of Diagnostic Pathology, National Hospital Organization Kure Medical Center and Chugoku Cancer Center, Kure 737-0023, Japan
3GLab Pathology Center Co., Ltd., Sapporo 060-0009, Japan
4Institute for Clinical Research, National Hospital Organization Kure Medical Center and Chugoku Cancer Center, Kure 737-0023, Japan

Received 24 January 2011; Accepted 22 March 2011

Academic Editor: Nirag Jhala

Copyright © 2011 Kazuhiro Takehara et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. F. X. Bosch, A. N. Burchell, M. Schiffman et al., “Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia,” Vaccine, vol. 26, supplement 10, pp. K1–K16, 2008. View at Publisher · View at Google Scholar · View at Scopus
  2. S. Miura, K. Matsumoto, A. Oki et al., “Do we need a different strategy for HPV screening and vaccination in East Asia?” International Journal of Cancer, vol. 119, no. 11, pp. 2713–2715, 2006. View at Publisher · View at Google Scholar · View at Scopus
  3. M. Onuki, K. Matsumoto, T. Satoh et al., “Human papillomavirus infections among Japanese women: age-related prevalence and type-specific risk for cervical cancer,” Cancer Science, vol. 100, no. 7, pp. 1312–1316, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. N. Muñoz, F. Xavier Bosch, X. Castellsagué et al., “Against which human papillomavirus types shall we vaccinate and screen? The international perspective,” International Journal of Cancer, vol. 111, no. 2, pp. 278–285, 2004. View at Publisher · View at Google Scholar · View at Scopus
  5. M. Nishiwaki, T. Yamamoto, S. Tone et al., “Genotyping of human papillomaviruses by a novel one-step typing method with multiplex PCR and clinical applications,” Journal of Clinical Microbiology, vol. 46, no. 4, pp. 1161–1168, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. H. Yoshikawa, C. Nagata, K. Noda et al., “Human papillomavirus infection and other risk factors for cervical intraepithelial neoplasia in Japan,” British Journal of Cancer, vol. 80, no. 3-4, pp. 621–624, 1999. View at Publisher · View at Google Scholar · View at Scopus
  7. T. Sasagawa, W. Basha, H. Yamazaki, and M. Inoue, “High-risk and multiple human papillomavirus infections associated with cervical abnormalities in Japanese women,” Cancer Epidemiology Biomarkers and Prevention, vol. 10, no. 1, pp. 45–52, 2001. View at Google Scholar · View at Scopus
  8. T. Asato, T. Maehama, Y. Nagai, K. Kanazawa, H. Uezato, and K. I. Kariya, “A large case-control study of cervical cancer risk associated with human papillomavirus infection in Japan, by nucleotide sequencing-based genotyping,” Journal of Infectious Diseases, vol. 189, no. 10, pp. 1829–1832, 2004. View at Publisher · View at Google Scholar · View at Scopus
  9. G. M. Clifford, J. S. Smith, T. Aguado, and S. Franceschi, “Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis,” British Journal of Cancer, vol. 89, no. 1, pp. 101–105, 2003. View at Publisher · View at Google Scholar · View at Scopus
  10. G. M. Clifford, J. S. Smith, M. Plummer, N. Muñoz, and S. Franceschi, “Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis,” British Journal of Cancer, vol. 88, no. 1, pp. 63–69, 2003. View at Publisher · View at Google Scholar · View at Scopus
  11. N. Muñoz, F. X. Bosch, S. De Sanjosé et al., “Epidemiologic classification of human papillomavirus types associated with cervical cancer,” The New England Journal of Medicine, vol. 348, no. 6, pp. 518–527, 2003. View at Publisher · View at Google Scholar · View at Scopus
  12. D. M. Harper, E. L. Franco, C. Wheeler et al., “Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial,” The Lancet, vol. 364, no. 9447, pp. 1757–1765, 2004. View at Publisher · View at Google Scholar · View at Scopus
  13. L. L. Villa, R. L. R. Costa, C. A. Petta et al., “Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial,” The Lancet Oncology, vol. 6, no. 5, pp. 271–278, 2005. View at Publisher · View at Google Scholar · View at Scopus
  14. P. K. S. Chan, T. H. Cheung, A. O. Y. Tam et al., “Biases in human papillomavirus genotype prevalence assessment associated with commonly used consensus primers,” International Journal of Cancer, vol. 118, no. 1, pp. 243–245, 2006. View at Publisher · View at Google Scholar · View at Scopus
  15. W. G. V. Quint, S. R. Pagliusi, N. Lelie, E. M. de Villiers, and C. M. Wheeler, “Results of the first World Health Organization international collaborative study of detection of human papillomavirus DNA,” Journal of Clinical Microbiology, vol. 44, no. 2, pp. 571–579, 2006. View at Publisher · View at Google Scholar · View at Scopus
  16. K. Taniyama, D. N. Jhala, H. Katayama et al., “Multinational comparison of diagnostic clues for uterine cervical lesions among cytotechnologists in Asian countries,” Diagnostic Cytopathology. In press.
  17. L. L. Villa, G. Perez, S. K. Kjaer et al., “Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions,” The New England Journal of Medicine, vol. 356, no. 19, pp. 1915–1927, 2007. View at Publisher · View at Google Scholar · View at Scopus
  18. D. M. Harper, E. L. Franco, C. M. Wheeler et al., “Sustained efficacy up to 4·5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial,” The Lancet, vol. 367, no. 9518, pp. 1247–1255, 2006. View at Publisher · View at Google Scholar · View at Scopus
  19. J. Paavonen, D. Jenkins, F. X. Bosch et al., “Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial,” The Lancet, vol. 369, no. 9580, pp. 2161–2170, 2007. View at Publisher · View at Google Scholar · View at Scopus
  20. J. Paavonen, P. Naud, J. Salmerón et al., “Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women,” The Lancet, vol. 374, no. 9686, pp. 301–314, 2009. View at Publisher · View at Google Scholar · View at Scopus
  21. S. de Sanjosé, M. Diaz, X. Castellsagué et al., “Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis,” The Lancet Infectious Diseases, vol. 7, no. 7, pp. 453–459, 2007. View at Publisher · View at Google Scholar · View at Scopus
  22. S. T. Lindau, M. L. Drum, E. Gaumer, H. Surawska, and J. A. Jordan, “Prevalence of high-risk human papillomavirus among older women,” Obstetrics and Gynecology, vol. 112, no. 5, pp. 979–989, 2008. View at Publisher · View at Google Scholar · View at Scopus